Archive for the ‘Bioprocessing and Bioanalytics’ Category

What you get for what you gave: Why yield is an important metric in the development of CGTs.

Author: Sowmya Viswanathan, 01/08/18

  In this month’s blog on addressing specific bioprocess and bioanalytical challenges to develop Cell and Gene Therapies (CGTs), we hear from Dr. Nick Timmins on quantifying performance of CGTs using cell yield, and some of the methods to measure it, as a metric of optimized manufacturing of CGTs. (SV) Nick Timmins is VP, Process…Read more

Bioprocessing and bioanalytics

Author: Sowmya Viswanathan, 11/30/17

The recent FDA approvals of Kymriah™ for the treatment of children and young adults with B-cell Acute Lymphoblastic Leukemia, and Yescarta™ to treat adults with certain types of non-Hodgkin lymphoma, and the unanimous endorsement by an FDA advisory committee of a gene therapy (LUXTURNA™)  has energized the fields of cell-and gene-based therapies. (Learn how gene…Read more